Position of Incretin Agents in the Traitement of Type 2 Diabetes Mellitus: Literature Review
Sara Deghima*, Smina Yahiaoui and Aissa Boudiba
Department of Diabetology, CHU Mustapha Pacha, Algiers- Algeria
- Corresponding Author:
- Sara Deghima
Department of Diabetology
CHU Mustapha Pacha, Algiers-Algeria
E-mail: [email protected]
Received Date: February 20, 2014; Accepted Date: February 27, 2014; Published Date: March 02, 2014
Citation: Deghima S, Yahiaoui S, Boudiba A (2014) Position of Incretin Agents in the Traitement of Type 2 Diabetes Mellitus: Literature Review. Endocrinol Metab Synd 3:123. doi: 10.4172/2161-1017.1000123
Copyright: © 2014 Deghima S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Type 2 diabetes is a chronic and progressive pathology that requires monitoring and supervision for life, its management is difficult and requires continuous efforts with essential therapeutic scaling for the maintaining good glycemic balance. Incretin agents are a new class of drugs that enriches the medical arsenal already available to treat type 2 diabetes; they represent a promising therapeutic option, because they do not cause hypoglycemia while having a beneficial or neutral effect on weight or even a reduction in cardiovascular risk. Through this literature review, we will explain the place of incretin agents in the management of type 2 diabetes and their interest.